Pars Plana Vitrectomy versus Intravitreal Injection of Ranibizumab in the Treatment of Diabetic Macular Edema Associated with Vitreomacular Interface Abnormalities
Table 1
Baseline characteristics of the patients in the two groups.
Group I
Group II
value
(n = 20)
(n = 20)
Gender
Male
8
(40%)
6
(30%)
Female
12
(60%)
14
(70%)
Age (years)
67 ± 8
63 ± 11
Diabetes
Type 1
0
(0%)
1
(5%)
Type 2
20
(100%)
19
(95%)
Diabetic retinopathy
Moderate NPDR
10
(50%)
5
(25%)
Severe NPDR
6
(30%)
3
(15%)
Quiescent PDR
4
(20%)
12
(60%)
HbA1c (%)
8.1 ± 0.4
8.2 ± 0.3
Previous treatment
None
13
(65%)
5
(25%)
IVIs of anti-VEGF/steroids
6
(30%)
8
(40%)
Macular laser
0
(0%)
4
(20%)
Both
1
(5%)
3
(15%)
VMIA
ERM
14
(70%)
11
(55%)
VMT
4
(20%)
6
(30%)
ERM and VMT
2
(10%)
3
(15%)
Subtype of VMIA
ERM
Partially adherent
8/16
(50%)
9/14
(64%)
Globally adherent
8/16
(50%)
5/14
(36%)
VMT
Broad
1/6
(17%)
3/9
(33%)
Focal
5/6
(83%)
6/9
(67%)
Lens
Phakic
12
(60%)
5
(25%)
Pseudophakic
8
(40%)
15
(75%)
CDVA (LogMAR)
0.78 ± 0.29
0.83 ± 0.28
CSFT (µm)
516 ± 93
527 ± 116
Statistically significant at . Group I: ranibizumab; Group II: pars plana vitrectomy; NPDR: nonproliferative diabetic retinopathy; PDR: proliferative diabetic retinopathy; HbA1c: hemoglobin A1c; IVIs: intravitreal injections; anti-VEGF: anti-vascular endothelial growth factor; VMIA: vitreomacular interface abnormalities; ERM: epiretinal membrane; VMT: vitreomacular traction; CDVA: corrected distance visual acuity; CSFT: central subfield thickness.
